Hospital
Harnett Health System, INC.
Harnett Health System, INC. was paid $23.37M by Medicaid between Jan 2018 and Dec 2024, across 130 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoHARNETT HEALTH SYSTEM, INC.
DUNN, NC 28334
DUNN, NC 28334
33aNPI1922144757assigned 01/29/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$23.37M
24GClaims698,334
24DCodes billed130
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in North Carolina
Rank by total paid#24 of 92
Median peer was paid$11.47M
This provider vs. median2.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FISER, JOSEPH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 116,198 | $2.69M | |
| 2019 | 117,345 | $2.68M | |
| 2020 | 72,508 | $1.83M | |
| 2021 | 90,634 | $3.45M | |
| 2022 | 99,369 | $4.58M | |
| 2023 | 104,343 | $4.07M | |
| 2024incomplete | 97,937 | $4.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 59,316 | 53,560 | $7.54M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 19% | 24,331 | 21,128 | $4.36M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 12% | 39,419 | 36,192 | $2.77M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 7.1% | 11,892 | 10,465 | $1.67M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.6% | 4,420 | 3,774 | $609K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.2% | 9,964 | 8,605 | $517K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.0% | 24,789 | 19,497 | $475K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.7% | 1,186 | 1,008 | $388K |
| G0378 | Hospital observation service, per hour | 1.6% | 4,269 | 2,537 | $369K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.4% | 18,189 | 14,470 | $335K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.3% | 6,440 | 5,683 | $303K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.2% | 41,423 | 35,495 | $279K |
118 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.1% | 449 | $259K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 5,021 | $251K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.0% | 33,490 | $240K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,510 | $204K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,528 | $201K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,588 | $198K |
| 87400 | <1% | 7,242 | $176K | |
| 71045 | Radiologic examination, chest; single view | <1% | 6,803 | $162K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,377 | $145K |
| J3490 | Unclassified drugs | <1% | 71,078 | $132K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 2,161 | $127K |
| 84484 | <1% | 22,011 | $126K | |
| 80053 | Comprehensive metabolic panel | <1% | 15,517 | $117K |
| 36415 | Collection of venous blood by venipuncture | <1% | 60,077 | $112K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 13,192 | $98K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 1,024 | $97K |
| 81000 | <1% | 28,566 | $96K | |
| 81025 | <1% | 12,401 | $92K | |
| 80076 | <1% | 13,110 | $85K | |
| A9270 | Non-covered item or service | <1% | 45,677 | $59K |
| 83690 | <1% | 9,203 | $59K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,194 | $57K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,292 | $52K |
| 85027 | <1% | 7,895 | $42K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 85 | $39K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,206 | $36K |
| 80329 | <1% | 748 | $35K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 828 | $35K |
| 81001 | <1% | 8,825 | $29K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 661 | $25K |
| 83735 | <1% | 4,768 | $20K | |
| 85730 | <1% | 5,425 | $20K | |
| 87081 | <1% | 3,070 | $20K | |
| 80320 | <1% | 605 | $20K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 487 | $17K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 512 | $16K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 7,723 | $16K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 455 | $14K |
| 85610 | <1% | 5,642 | $14K | |
| 82728 | <1% | 1,136 | $12K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 626 | $12K |
| 83605 | <1% | 1,691 | $12K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 106 | $10K |
| 82550 | <1% | 2,840 | $10K | |
| 83880 | <1% | 539 | $9K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 6,533 | $9K |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 850 | $8K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 131 | $8K |
| 83550 | <1% | 1,072 | $8K | |
| 59025 | Fetal non-stress test | <1% | 143 | $8K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 258 | $6K |
| 88304 | <1% | 71 | $6K | |
| 87807 | <1% | 454 | $6K | |
| 97597 | <1% | 242 | $6K | |
| 81003 | <1% | 2,171 | $5K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 102 | $4K |
| 84702 | <1% | 434 | $4K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 155 | $4K |
| 94760 | <1% | 1,001 | $4K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 26 | $4K |
| 87040 | <1% | 944 | $4K | |
| 82607 | <1% | 289 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 2,405 | $3K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 81 | $3K |
| 82746 | <1% | 263 | $3K | |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 116 | $3K |
| 80143 | <1% | 987 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 696 | $2K |
| 74022 | <1% | 53 | $2K | |
| 87070 | <1% | 192 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 12 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 289 | $2K |
| 83540 | <1% | 267 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 574 | $2K |
| 82150 | <1% | 306 | $2K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 40 | $1K |
| 96376 | <1% | 70 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 229 | $1K |
| 87186 | <1% | 171 | $1K | |
| 87088 | <1% | 136 | $1K | |
| 80061 | Lipid panel | <1% | 100 | $932.04 |
| 82077 | <1% | 1,031 | $861.57 | |
| 80179 | <1% | 749 | $814.16 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 184 | $807.82 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 120 | $723.67 |
| 82947 | <1% | 284 | $695.74 | |
| 0598T | <1% | 24 | $693.06 | |
| 84100 | <1% | 325 | $682.03 | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 26 | $643.98 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 26 | $643.89 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 253 | $626.21 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 41 | $550.94 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | <1% | 16 | $470.44 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 332 | $449.95 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 21 | $392.65 |
| 82784 | <1% | 24 | $367.10 | |
| 85379 | <1% | 36 | $358.20 | |
| 86334 | <1% | 17 | $294.49 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 32 | $266.11 |
| 86850 | <1% | 28 | $201.05 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 27 | $192.21 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 169 | $155.19 |
| 86592 | <1% | 30 | $153.99 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 202 | $133.91 |
| 86901 | <1% | 60 | $108.64 | |
| 86900 | <1% | 60 | $104.05 | |
| 81005 | <1% | 46 | $103.94 | |
| 83521 | <1% | 23 | $62.55 | |
| 87075 | <1% | 19 | $58.19 | |
| 83615 | <1% | 16 | $56.60 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 24 | $51.17 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 37 | $43.87 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 60 | $28.57 |
| 87205 | <1% | 19 | $26.20 | |
| J1815 | Injection, insulin, per 5 units | <1% | 27 | $17.19 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 12 | $9.01 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 33 | $3.13 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 16 | $1.86 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFISER, JOSEPH (VP CORP REV CYCLE/MANAGED CARE)
Parent organizationHARNETT HEALTH SYSTEM INC
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.